全文获取类型
收费全文 | 1638篇 |
免费 | 100篇 |
国内免费 | 81篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 71篇 |
妇产科学 | 18篇 |
基础医学 | 276篇 |
口腔科学 | 23篇 |
临床医学 | 277篇 |
内科学 | 396篇 |
皮肤病学 | 50篇 |
神经病学 | 86篇 |
特种医学 | 310篇 |
外科学 | 77篇 |
综合类 | 27篇 |
预防医学 | 31篇 |
眼科学 | 11篇 |
药学 | 94篇 |
肿瘤学 | 69篇 |
出版年
2022年 | 3篇 |
2021年 | 8篇 |
2019年 | 13篇 |
2018年 | 8篇 |
2017年 | 11篇 |
2016年 | 17篇 |
2015年 | 21篇 |
2014年 | 18篇 |
2013年 | 35篇 |
2012年 | 13篇 |
2011年 | 22篇 |
2010年 | 54篇 |
2009年 | 53篇 |
2008年 | 32篇 |
2007年 | 64篇 |
2006年 | 24篇 |
2005年 | 40篇 |
2004年 | 22篇 |
2003年 | 24篇 |
2002年 | 32篇 |
2001年 | 30篇 |
2000年 | 32篇 |
1999年 | 41篇 |
1998年 | 101篇 |
1997年 | 97篇 |
1996年 | 114篇 |
1995年 | 91篇 |
1994年 | 97篇 |
1993年 | 80篇 |
1992年 | 48篇 |
1991年 | 55篇 |
1990年 | 45篇 |
1989年 | 54篇 |
1988年 | 49篇 |
1987年 | 49篇 |
1986年 | 55篇 |
1985年 | 40篇 |
1984年 | 23篇 |
1983年 | 31篇 |
1982年 | 30篇 |
1981年 | 32篇 |
1980年 | 18篇 |
1979年 | 15篇 |
1978年 | 11篇 |
1977年 | 24篇 |
1976年 | 14篇 |
1975年 | 9篇 |
1974年 | 4篇 |
1973年 | 3篇 |
1971年 | 4篇 |
排序方式: 共有1819条查询结果,搜索用时 15 毫秒
1.
Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits 总被引:1,自引:0,他引:1
G Defreyn C Gachet P Savi F Driot J P Cazenave J P Maffrand 《Thrombosis and haemostasis》1991,65(2):186-190
Ticlopidine and its potent analogue, clopidogrel, are powerful inhibitors of ADP-induced platelet aggregation. In order to improve the understanding of this ADP-selectivity, we studied the effect of these compounds on PGE1-stimulated adenylate cyclase and on the inhibition of this enzyme by ADP, epinephrine and thrombin. Neither drug changed the basal cAMP levels nor the kinetics of cAMP accumulation upon PGE1-stimulation in rat or rabbit platelets, which excludes any direct effect on adenylate cyclase or on cyclic nucleotide phosphodiesterase. However, the drop in cAMP levels observed after addition of ADP to PGE1-stimulated control platelets was inhibited in platelets from treated animals. In contrast, the drop in cAMP levels produced by epinephrine was not prevented by either drug in rabbit platelets. In rat platelets, thrombin inhibited the PGE1-induced cAMP elevation but this effects seems to be entirely mediated by the released ADP. Under these conditions, it was not surprising to find that clopidogrel also potently inhibited that effect of thrombin on platelet adenylate cyclase. In conclusion, ticlopidine and clopidogrel selectively neutralize the ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits. 相似文献
2.
3.
4.
5.
6.
7.
8.
Y Leskinen JP Salenius T Lehtim?ki H Huhtala H Saha 《American journal of kidney diseases》2002,40(3):472-479
BACKGROUND: Knowledge of the prevalence of peripheral arterial disease (PAD) in patients with chronic renal failure (CRF) is limited because of a lack of uniformity in disease definition and recognition. Furthermore, little is known of the prevalence of medial arterial calcification (MAC) in patients with CRF. Our goal is to study the prevalence of PAD and MAC defined by ankle brachial index (ABI) or toe brachial index (TBI) measurements in a Finnish population of patients with CRF consisting of predialysis and dialysis patients, as well as renal transplant recipients. METHODS: We examined 136 patients with CRF and 59 control subjects. Fifty-nine of the patients with CRF had moderate to severe predialysis CRF, 36 patients were on dialysis treatment, and 41 were renal transplant recipients. Mean age of patients was 51.9 +/- 11.5 years, and 39 patients (29%) had diabetes. ABI and TBI were measured by means of photoplethysmography. The definition of PAD required an ABI value of 0.90 or less, a TBI value of 0.60 or less, or a previous positive lower-extremity angiogram result. ABI values of 1.3 or greater or incompressible arteries at ankle level indicated MAC. The presence of claudication was determined by an interview. RESULTS: Prevalences of PAD on this study were 22.0% in patients with predialysis CRF, 30.6% in patients on dialysis treatment, 14.6% in renal transplant recipients, and 1.7% in the control group (P = 0.001). Prevalences of MAC were 23.7%, 41.7%, 23.1%, and 3.4% (P < 0.001), respectively. Only 9 patients had claudication, and 6 of those patients had PAD. CONCLUSION: Both asymptomatic PAD and MAC are common in patients with CRF. Therefore, we recommend the use of both ABI and TBI measurements in the evaluation of PAD in patients with CRF. 相似文献
9.
F Lanza J P Cazenave A Beretz A Sutter-Bay J G Kretz R Kieny 《Agents and actions》1986,18(5-6):586-595
Adrenaline (1 to 10 microM) can induce the aggregation of human platelets suspended in citrated plasma but does not induce the aggregation of washed human platelets at doses as high as 1 mM, although these platelets respond normally to ADP, PAF-acether, collagen, arachidonic acid, thrombin, the endoperoxide analog U-46619 and the Ca2+ ionophore A23187. Adrenaline (0.5 microM) potentiates the aggregation and secretion induced by all the previous agonists in citrated platelet-rich plasma (cPRP) or in washed platelets. The activation by adrenaline of human platelets is mediated by alpha 2-adrenergic receptors, as demonstrated by inhibition with a series of adrenergic antagonists. The alpha-adrenergic antagonist nicergoline inhibits the activation of human platelets by adrenaline in the following situations: nicergoline inhibits the aggregation and secretion caused by adrenaline in cPRP (IC50 0.22 microM and 0.28 microM respectively); nicergoline inhibits the aggregation and secretion induced by the combination of adrenaline and each aggregating agent listed above in cPRP (IC50 ranging from 0.1 to 2.5 microM) or in washed platelets (IC50 ranging from 0.1 to 0.8 microM); nicergoline inhibits the binding of 3H-yohimbine to washed human platelets (IC50 0.26 microM); the intravenous administration of nicergoline (0.5 mg/kg per day) to patients inhibits significantly the ex vivo response of their platelets to adrenaline in cPRP. High concentrations of nicergoline also inhibit the aggregation and secretion induced by the aggregating agents listed above in cPRP (IC50 range 108 to 670 microM) and in washed platelets (IC50 range 27 to 140 microM) and the adhesion of platelets to collagen-coated surfaces. This latter effect is not mediated through blockade of alpha-adrenoceptors. A possible role of adrenaline in platelet activation in vivo could justify the use of nicergoline (Sermion), an alpha-adrenergic antagonist in combination therapy to prevent arterial thrombosis. 相似文献
10.
We used arthrotomography to study the glenoid labrum in 114 patients. Sixty-nine of the patients had anatomic instability of the shoulder (including recurrent dislocation and subluxation of the shoulder), and 45 patients had functional instability of the shoulder (denoted by chronic pain, clicking of the joint, and the sensation that an unstable condition exists without the objective signs of it). Labral tears were revealed arthrotomographically in 86% of the patients with anatomic instability, while only 40% of the patients with functional instability had labral abnormalities, and these were primarily of minor severity. Fifty-six patients (44 of whom had anatomic instability; 12, functional instability) required surgery. The surgical findings were correlated with the arthrotomographic findings, and no false-positive results were revealed. However, arthrotomography demonstrated only part of the pathologic condition of two patients. These results confirm that there is a strong correlation between labral pathologic conditions and anatomic instability of the shoulder. Arthrotomographic studies have a great impact on the selection of therapy in cases of both anatomic and functional instability of the shoulder. 相似文献